Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapy options in imatinib failures.

The oncologist - 1 Apr 2008

Ramirez Pablo, DiPersio John F

Abstract excerpt

Chronic myelogenous leukemia (CML) is defined by the presence of the constitutively active tyrosine kinase breakpoint cluster region/Abelson (Bcr-Abl), which activates numerous signal transduction pathways leading to uncontrolled cell proliferation. The development of the Bcr-Abl-targeted imatinib represents a paradigm shift in the treatment of CML, because treatment with imatinib resulted in significantly better...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Thiazoles

Share to Treatment Failure

Source

Identifiers

PMID: 18448557
DOI: 10.1634/theoncologist.2007-0170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapy options in imatinib failures.PMID 18448557Read ↗

Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Semantic proximity Read ↗

New directions in the treatment of imatinib failure and/or resistance.Semantic proximity Read ↗

Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.Semantic proximity Read ↗

Defining and managing imatinib resistance.Semantic proximity Read ↗

P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Loss of response to imatinib: mechanisms and management.Semantic proximity Read ↗

Treatment of chronic myeloid leukemia when imatinib fails.Semantic proximity Read ↗

Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?Semantic proximity Read ↗

Third-generation tyrosine kinase inhibitors and beyond.Semantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.